Skin Integrity Team has been shortlisted in three categories at this year’s Journal of Wound Care Awards, which take place ...

North America remains the largest market for skin perfusion pressure testing devices, driven by rising cardiovascular disease ...

Charcot neuroarthropathy is a severe complication often linked to diabetes, causing progressive bone and joint damage in the feet. Surgical intervention is ...

MediWound has commenced a pivotal, multicentre Phase III VALUE trial to assess its bioactive debridement therapy, EscharEx, ...

The company said its EscharEx treatment had previously demonstrated its ability to effectively and rapidly remove damaged or ...

BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in wound healing and wound care products, is pleased to announce the approval of its randomized control trial designed to ...

YAVNE, Israel - MediWound Ltd. (NASDAQ:MDWD), a biopharmaceutical company specializing in enzymatic therapies for tissue repair, has launched a Phase III clinical trial for its product EscharEx®, ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

As home health providers increasingly serve people with more complicated and serious conditions, and the push for cost-effective and value-based care ...

In the heart of Sioux Falls, at Dakota Vascular, you’ll find Dr. Pat Kelly, a physician whose story is as inspiring as it is ...

A key driver is the rising prevalence of chronic wounds. The global wound care devices market is projected to hit $4b by 2032 ...